Amgen reiterated at neutral by Credit Suisse

Amgen Inc. was reiterated at neutral with a target price of $76 by Credit Suisse analyst Mark Augustine after the company announced Aranesp phase 2 results from one of three studies in heart failure. The analyst noted in the safety study a higher rate of death in Aranesp-treated patients (six cases versus zero in the placebo group). Shares of the Thousand Oaks, Calif., biotechnology company were up $1.42, or 1.93%, at $75.01 on volume of 8,409,219 shares versus the three-month running average of 10,465,900 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.